Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail

v3.7.0.1
Condensed Consolidated Financial Statements Detail
6 Months Ended
Jun. 30, 2017
Condensed Consolidated Financial Statements Detail [Abstract]  
Condensed Consolidated Financial Statements Detail

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

As of June 30, 2017, cash and cash equivalents consisted of demand deposits of $2.6 million and money market funds of $9.9 million with maturities of less than 90 days at the date of purchase. As of December 31, 2016, cash and cash equivalents consisted of demand deposits of $21.5 million and money market funds of $4.2 million with maturities of less than 90 days at the date of purchase.

Trade and Other Receivables, net

Trade receivables are stated at their net realizable value. Specific allowances are recorded for doubtful accounts or based on other available information. The Company reviews its exposure to accounts receivable, including the requirement for allowances based on management’s judgment. The Company has not historically experienced any significant losses.

Trade and other receivables consisted of the following (in thousands):

 

 

June 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Trade receivables, net

 

$

10,546

 

 

$

474

 

Other receivables

 

 

85

 

 

 

92

 

Trade and other receivables, net

 

$

10,631

 

 

$

566

 

Property and Equipment, net

Property and equipment, net consisted of the following (in thousands):

 

 

June 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Equipment and furniture

 

$

1,921

 

 

$

14,023

 

Leasehold improvements

 

 

334

 

 

 

554

 

 

 

 

2,255

 

 

 

14,577

 

Less: Accumulated depreciation and amortization

 

 

(2,021

)

 

 

(13,541

)

Property and equipment, net

 

$

234

 

 

$

1,036

 

During the six months ended June 30, 2017, the Company completed the sale of equipment and disposal of certain equipment located in one of its leased facilities for total proceeds of $1.6 million. The total carrying value of the equipment sold and disposed of was $0.4 million. Accordingly, the Company recorded a loss of $88,000 and gain of $1.2 million on the sale and disposal of equipment in the other income (expense), net line of the condensed consolidated statements of comprehensive income (loss) for the three and six months ended June 30, 2017, respectively.

Accrued and Other Liabilities  

Accrued and other liabilities consisted of the following (in thousands):

 

 

June 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

Accrued payroll and other benefits

 

$

138

 

 

$

1,582

 

Accrued clinical trial costs

 

 

389

 

 

 

743

 

Accrued incentive compensation

 

 

134

 

 

 

 

Accrued legal and accounting fees

 

 

641

 

 

 

385

 

Other

 

 

760

 

 

 

1,505

 

Total

 

$

2,062

 

 

$

4,215

 

 

Net Income (Loss) Per Share Available to Common Stockholders

The following is a reconciliation of the numerator (net income or loss) and the denominator (number of shares) used in the calculation of basic and diluted net income (loss) per share available to common stockholders (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Numerator

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

285

 

 

$

(15,160

)

 

$

(10,429

)

 

$

(23,525

)

Less: Deemed dividend on convertible preferred stock

 

 

 

 

 

 

 

 

(5,603

)

 

 

 

Less: Allocation of undistributed earnings to participating securities

 

 

(113

)

 

 

 

 

 

 

 

 

 

Net income (loss) available to common stockholders, basic and diluted

 

$

172

 

 

$

(15,160

)

 

$

(16,032

)

 

$

(23,525

)

Denominator

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding used for basic net income (loss) per share available to common stockholders

 

 

7,588

 

 

 

6,022

 

 

 

7,240

 

 

 

6,000

 

Effect of dilutive stock options

 

 

55

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding used for diluted net income (loss) per share available to common stockholders

 

 

7,643

 

 

 

6,022

 

 

 

7,240

 

 

 

6,000

 

Potentially dilutive securities are excluded from the calculation of diluted net income (loss) per share available to common stockholders if their inclusion is anti-dilutive. The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net income (loss) per share available to common stockholders (in thousands):

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Convertible preferred stock (as converted)

 

 

 

 

 

 

 

 

3,732

 

 

 

 

Common stock options and RSUs

 

 

1,138

 

 

 

554

 

 

 

1,391

 

 

 

544

 

Warrants for common stock

 

 

19

 

 

 

917

 

 

 

19

 

 

 

914

 

Total

 

 

1,157

 

 

 

1,471

 

 

 

5,142

 

 

 

1,458